Griffin Asset Management, Inc. Incyte Corp Transaction History

Griffin Asset Management, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 18, 2020	SELL	$63.18 - $85.97 $174,250 - $237,105	-2,758 Closed	0 $0
Q4 2019 Feb 11, 2020	BUY	$73.04 - $95.72 $201,444 - $263,995	2,758 New	2,758 $241,000
Q3 2019 Nov 05, 2019	SELL	$72.82 - $86.52 $237,029 - $281,622	-3,255 Closed	0 $0
Q2 2019 Aug 19, 2019	BUY	$73.52 - $88.7 $63,594 - $76,725	865 Added 36.19%	3,255 $277,000
Q1 2019 May 08, 2019	BUY	$63.56 - $88.17 $151,908 - $210,726	2,390 New	2,390 $206,000
Q1 2018 May 16, 2018	SELL	$83.06 - $100.98 $175,671 - $213,572	-2,115 Closed	0 $0
Q4 2017 Feb 20, 2018	BUY	$93.56 - $116.6 $197,879 - $246,609	2,115	2,115 $200,000

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Griffin Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Griffin Asset Management, Inc. with notifications on news.